A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL	B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-06-04		NCT04722172

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Genentech, Inc.	221
Memorial Sloan Kettering Cancer Center	753

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hackensack Meridian Health (Data Collection Only)	Hackensack	United States	6
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge	United States	56
Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale	United States	82
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	United States	230
Memorial Sloan Kettering Commack (All Protocol Activities)	Commack	United States	20
Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown	United States	92
Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale	United States	53
Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison	United States	86